World News

Under the agreement, Lighthouse Two will subscribe for newly issued shares representing approximately 16.7% of LifeTech’s enlarged share capital.

The facility will increase capacity for drug-device combination products, including formulation development and the manufacture of supplies for early- and late-stage clinical trials.

Under the research agreement, the US biotechnology company will collaborate with Duke researchers to conduct molecular profiling of tissue and blood samples stored in the university’s biobanks.

The drug, which will be marketed under the brand name Ashuli, is the first biosimilar of Johnson & Johnson’s Simponi (golimumab) to receive marketing authorisation in China.

Yuri Vasilev, the Centre’s Medical Director, received the Quality Director 2026 award, while Alexander Borisov, a researcher in its Department of Medical Informatics, Radiomics and Radiogenomics, won the Breakthrough of the Year category.

Under the proposed terms, existing Brains Bioceutical shareholders will roll over their entire equity interests into the newly listed company.

The expanded indication covers both radiographic and non-radiographic forms of axSpA in adults who have not responded adequately to conventional treatment or cannot tolerate it.

The platform comes as the United Nations Human Rights Council prepares for another round of its Universal Periodic Review (UPR) in November 2026, renewing attention to how countries implement their international human rights obligations.

The collaboration aims to improve the diagnosis of rare genetic conditions that can cause unexplained symptoms, affect multiple organ systems or resemble other diseases.

The approval covers adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) whose disease has progressed during or after platinum-based chemotherapy and treatment with an anti-PD-(L)1 antibody.